Article info

Download PDFPDF

Original research
Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort

Authors

  • Joanna Kedra Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, FranceAPHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France PubMed articlesGoogle scholar articles
  • Alexandre Lafourcade Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, France PubMed articlesGoogle scholar articles
  • Bernard Combe Rheumatology, CHU Montpellier, Montpellier, France PubMed articlesGoogle scholar articles
  • Maxime Dougados Hopital Cochin (AP-HP), Rheumatology, Université de Paris, Paris, France PubMed articlesGoogle scholar articles
  • David Hajage Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, FranceCentre de Pharmacoépidémiologie (Cephepi), APHP Pitié-Salpêtrière Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Bruno Fautrel Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, FranceAPHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Joanna Kedra; jkedra.pro{at}gmail.com
View Full Text

Citation

Kedra J, Lafourcade A, Combe B, et al
Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort

Publication history

  • Received October 18, 2021
  • Accepted February 22, 2022
  • First published May 9, 2022.
Online issue publication 
May 09, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.